Why the study?
Does ischemic versus nonischemic etiology affect reverse LV remodeling and symptom benefit with CRT in patients with NYHA class III/IV heart failure?
Does ischemic versus nonischemic etiology affect reverse LV remodeling and symptom benefit with CRT in patients with NYHA class III/IV heart failure?
Patients with nonischemic heart failure experience greater reverse LV remodeling and symptom benefit from CRT at 1 year compared to those with ischemic etiology.
Etiology may guide CRT outcome expectations; extends observational data on differential response but remains hypothesis-generating.
Reverse LV remodeling and symptom benefit with CRT are sustained at 12 months in patients with New York Heart Association class III/IV heart failure but occur to a lesser degree in patients with an ischemic versus a nonischemic etiology, most likely owing to the inexorable progression of ischemic disease.
No takes yet. Share an insight, caveat, or question.
Sutton et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: